129 related articles for article (PubMed ID: 10844404)
1. Thromboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. The TIFDED Study Group.
Haemostasis; 1999; 29(6):310-7. PubMed ID: 10844404
[TBL] [Abstract][Full Text] [Related]
2. Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
Taylor AA
BJOG; 2001 Sep; 108(9):1011-2. PubMed ID: 11563455
[No Abstract] [Full Text] [Related]
3. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson T; Perry CM
Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
5. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
6. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for bleeding during treatment of acute venous thromboembolism.
Wester JP; de Valk HW; Nieuwenhuis HK; Brouwer CB; van der Graaf Y; Meuwissen OJ; Hart HC; Sixma JJ; Banga JD
Thromb Haemost; 1996 Nov; 76(5):682-8. PubMed ID: 8950773
[TBL] [Abstract][Full Text] [Related]
10. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group.
Comp PC; Voegeli T; McCutchen JW; Skoutakis VA; Trowbridge A; Overdyke WL
Orthopedics; 1998 Oct; 21(10):1123-8. PubMed ID: 9801236
[TBL] [Abstract][Full Text] [Related]
11. Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.
Lapidus LJ; Ponzer S; Elvin A; Levander C; Lärfars G; Rosfors S; de Bri E
Acta Orthop; 2007 Aug; 78(4):528-35. PubMed ID: 17966008
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
Wade WE
Am J Orthop (Belle Mead NJ); 1999 Apr; 28(4):229-31. PubMed ID: 10220094
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture.
Gent M; Hirsh J; Ginsberg JS; Powers PJ; Levine MN; Geerts WH; Jay RM; Leclerc J; Neemeh JA; Turpie AG
Circulation; 1996 Jan; 93(1):80-4. PubMed ID: 8616946
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
15. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
16. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
Miyake Y; Yokota K; Fujishima Y; Sukamoto T
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
19. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70.
Bergqvist D; Kettunen K; Fredin H; Faunø P; Suomalainen O; Soimakallio S; Karjalainen P; Cederholm C; Jensen LJ; Justesen T
Surgery; 1991 May; 109(5):617-22. PubMed ID: 1708528
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Jeong GK; Gruson KI; Egol KA; Aharonoff GB; Karp AH; Zuckerman JD; Koval KJ
Am J Orthop (Belle Mead NJ); 2007 Mar; 36(3):135-40. PubMed ID: 17461395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
